RESUMO
Yersinia enterocolitica septicaemia is an infrequent condition. We report a case in which septicaemia developed after an infusion of desferrioxamine in a man with idiopathic haemochromatosis. According to the literature, the association of idiopathic haemochromatosis, liver disease and desferrioxamine therapy is extremely favourable to the development of Yersinia septicaemia because iron intake is known to enhance the virulence of this organism, and desferrioxamine, acting like a chelator, enables Yersinia to incorporate iron, which it does not normally do.
Assuntos
Desferroxamina/efeitos adversos , Hemocromatose/tratamento farmacológico , Sepse/etiologia , Yersinia enterocolitica/isolamento & purificação , Desferroxamina/administração & dosagem , Desferroxamina/uso terapêutico , Humanos , Infusões Intravenosas , Masculino , Pessoa de Meia-Idade , Fatores de Risco , Sepse/microbiologiaRESUMO
70 patients with advanced transitional cell carcinoma of the bladder received methotrexate, vinblastine, doxorubicin and cisplatin (M-VAC). Complete responses (CR) were obtained in 13 of the 67 (19%) evaluable patients and partial responses (PR) in 25 patients for an objective response rate of 57% (95% CI 45-69%). Of the 54 patients who have had a minimum follow-up of 2 years, 8 patients (15%) are disease-free or have stable residual disease. Median survival of the 70 patients was 13 months. Toxicity was acceptable with no drug-related deaths. Because of myelosuppression, only 15 patients (21%) received treatment without delays in drug administration or modifications from the planned schedule. Our results confirm that this regimen is effective, with some patients being long-term survivors.
Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Carcinoma de Células de Transição/tratamento farmacológico , Neoplasias da Bexiga Urinária/tratamento farmacológico , Adulto , Idoso , Agranulocitose/induzido quimicamente , Cisplatino/administração & dosagem , Cisplatino/efeitos adversos , Doxorrubicina/administração & dosagem , Doxorrubicina/efeitos adversos , Feminino , Humanos , Masculino , Metotrexato/administração & dosagem , Metotrexato/efeitos adversos , Pessoa de Meia-Idade , Prognóstico , Trombocitopenia/induzido quimicamente , Neoplasias da Bexiga Urinária/mortalidade , Vimblastina/administração & dosagem , Vimblastina/efeitos adversosRESUMO
In a phase II trial 2 N-Methyl-9-Hydroxy-Ellipticine (NMHE) was administered in weekly infusions of 100mg/m2 over 1 hour to patients with malignant metastases. Prior to injection, the drug was dissolved in 250 ml isotonic glucose. The results were evaluated in 67 patients. Objective regression was observed in 23 (34%) and was superior to 50% in 10 cases. Patients showing signs of regression under treatment were mostly those with breast cancer (10/24 cases), soft tissue sarcoma (3/9 cases) and renal cancer (2/8 cases). The main toxic effect was haemolysis (2 cases), probably due to an immunoallergic mechanism. Attention is drawn to the lack of bone marrow toxicity.
Assuntos
Alcaloides/uso terapêutico , Antineoplásicos/uso terapêutico , Elipticinas/uso terapêutico , Metástase Neoplásica/tratamento farmacológico , Antineoplásicos/administração & dosagem , Antineoplásicos/efeitos adversos , Neoplasias da Mama , Elipticinas/administração & dosagem , Elipticinas/efeitos adversos , Hemólise/efeitos dos fármacos , Humanos , Neoplasias Renais , Sarcoma , Neoplasias de Tecidos MolesRESUMO
One hundred and one patients with terminal cancer suffering severe pains reluctant to other treatment have received morphine by mouth, in a regular regimen. The doses range between 5 and 60 mg every 4 hours. 71 p. cent of our patients have their pain alleviated without any side effect impeding the treatment.
Assuntos
Morfina/administração & dosagem , Neoplasias/complicações , Dor/tratamento farmacológico , Administração Oral , Doença Crônica , Humanos , Morfina/efeitos adversos , Dor/etiologiaRESUMO
Fifty one patients with terminal cancer suffering severe pains reluctant to other treatment have received morphine by mouth, in a regular regimen. The doses range between 5 and 50 mg every 4 hours. 60% of our patients have their pain alleviated without any side effect impeding the treatment.